Advertisement - Members don't see this ad
From APA Headlines:
Teva begins shipments of risperidone.
The Wall Street Journal (7/1, B4) reports, "Teva Pharmaceutical Industries, Ltd. received Food and Drug Administration approval for its generic version of schizophrenia treatment Risperdal (risperidone), developed by Johnson & Johnson (J&J) unit Janssen Pharmaceuticals. Janssen's market exclusivity for Risperdal expired Sunday." The company "said it has begun shipments." The Wall Street Journal's (6/30, Wang) Health Blog also covered the story.

